AI-Powered Diagnostics and the Regulatory Frontier: What Health Tech Companies Need to Know

FDA regulates AI-enabled diagnostic and clinical decision support tools as Software as a Medical Device (SaMD) when intended to diagnose, treat, mitigate, or prevent a disease or condition. The applicable clearance pathway — 510(k), De Novo, or PMA — turns on risk classification and predicate device availability.

For AI/ML tools that learn and evolve post-market, FDA’s Predetermined Change Control Plan (PCCP) framework allows post-clearance algorithm modifications without a new 510(k) — but only if changes, validation protocols, and performance monitoring are documented and approved upfront. Companies that build products first and plan regulatory strategy second consistently face the most expensive rework.

Cybersecurity is now a mandatory submission element. FDA requires a Software Bill of Materials (SBOM), vulnerability management plan, and evidence of secure development practices in all 510(k) and PMA submissions. Separately, several states are advancing legislation governing algorithmic bias in healthcare and patient consent for AI-driven diagnoses — obligations that operate alongside, not inside, FDA’s framework. Digital health companies must track both tracks simultaneously.